Praxis Precision Medicines
PRAX
278.02
-2.12
-0.76%
Praxis Precision Medicines
US · PRAX
#1645 by market cap
Listed 2020
278.02
-2.12
-0.76%
Live - 5344 symbols - heartbeat 299s ago
· 2026-10-08 04:00
Pre-market
278.02
0.00%
After-hours
280.00
+0.71%
Overnight
276.72
-0.47%
- Market cap
- 7.76B
- P/E (TTM)i
- -21.45
- P/Bi
- 5.79
- EPSi
- -13.48
- Div yieldi
- 0.00%
- 52W posi
- 66%
Reader sentiment
Are you bullish or bearish on PRAX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 75.78, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -100.00% YoY
Margins
Key ratios & quality
- Altman Z-Scorei
- 75.78
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0 | 2.45M | 8.55M | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.90M | 6.23M | 16.99M | 47.08M | 59.95M | 42.05M | 56.31M | 59.08M |
| Research & development | 18.82M | 29.56M | 44.98M | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
| Operating profit | -22.72M | -35.79M | -61.97M | -167.33M | -214.99M | -126.37M | -200.17M | -326.20M |
| Pretax profit | -26.40M | -35.60M | -61.83M | -167.06M | -214.03M | -123.28M | -182.82M | -303.27M |
| Tax | 133.00K | -84.00K | -8.00K | -- | -- | -- | -- | -- |
| Net profit | -26.54M | -35.51M | -61.82M | -167.06M | -214.03M | -123.28M | -182.82M | -303.27M |
| Basic EPS | -33 | -36 | -118 | -59 | -70 | -19 | -10 | -13 |
| Diluted EPS | -33.03 | -35.53 | -117.90 | -59.10 | -69.65 | -18.69 | -10.21 | -13.48 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 0 | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 13.92M | 13.06M | 12.56M | 19.54M | 27.87M | 27.49M |
| Research & development | 60.81M | 63.01M | 65.80M | 77.51M | 77.99M | 69.42M |
| Operating profit | -74.73M | -76.07M | -78.36M | -97.04M | -105.86M | -96.90M |
| Pretax profit | -69.30M | -71.13M | -73.93M | -88.91M | -92.56M | -83.72M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -69.30M | -71.13M | -73.93M | -88.91M | -92.56M | -83.72M |
| Basic EPS | -3 | -3 | -3 | -4 | -3 | -3 |
| Diluted EPS | -3.29 | -3.31 | -3.36 | -3.50 | -3.20 | -2.87 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 19.13M | 45.50M | 302.33M | 287.41M | 110.84M | 84.88M | 404.37M | 610.91M |
| Cash & ST investments | 17.95M | 44.82M | 296.61M | 275.91M | 100.49M | 81.30M | 392.57M | 599.33M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 19.83M | 47.69M | 303.18M | 292.75M | 115.13M | 87.95M | 483.11M | 937.91M |
| Total current liabilities | 5.15M | 6.82M | 15.72M | 38.43M | 34.35M | 15.75M | 37.55M | 59.77M |
| Short-term debt | -- | 696.00K | 763.00K | 810.00K | 1.01M | 1.13M | 1.26M | 110.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 5,147,000.00 | 7,581,000.00 | 15,720,000.00 | 41,935,000.00 | 39,022,000.00 | 18,279,000.00 | 37,660,000.00 | 59,771,000.00 |
| Total equity | 14.68M | 40.11M | 287.46M | 250.81M | 76.11M | 69.67M | 445.45M | 878.14M |
| Retained earnings | -41.37M | -81.01M | -149.55M | -316.62M | -530.64M | -653.92M | -836.74M | -1.14B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 333.58M | 306.58M | 273.84M | 610.91M | 797.77M | 771.90M |
| Cash & ST investments | 327.99M | 301.28M | 267.16M | 599.33M | 786.87M | 758.55M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 478.74M | 452.83M | 396.39M | 937.91M | 1.46B | 1.39B |
| Total current liabilities | 39.52M | 48.61M | 52.88M | 59.77M | 50.24M | 49.06M |
| Short-term debt | 1.07M | 755.00K | 436.00K | 110.00K | 1.44M | 1.09M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 39,522,000.00 | 48,608,000.00 | 52,883,000.00 | 59,771,000.00 | 50,241,000.00 | 49,058,000.00 |
| Total equity | 439.21M | 404.22M | 343.51M | 878.14M | 1.41B | 1.34B |
| Retained earnings | -906.04M | -977.16M | -1.05B | -1.14B | -1.23B | -1.32B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -20.72M | -33.42M | -52.62M | -124.55M | -185.04M | -111.14M | -131.76M | -249.07M |
| Depreciation & amortization | 1.00K | 37.00K | 50.00K | 182.00K | 419.00K | 432.00K | 358.00K | 140.00K |
| Free cash flow | -20.78M | -33.52M | -52.62M | -125.60M | -185.49M | -111.19M | -131.76M | -249.12M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 200.89M | 105.71M | 9.56M | 91.59M | 512.00M | 690.99M |
| Ending cash balance | 18.55M | 45.42M | 297.21M | 139.72M | 62.03M | 81.72M | 215.79M | 357.75M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -53.01M | -54.68M | -65.06M | -76.33M | -86.15M | -77.54M |
| Depreciation & amortization | 47.00K | 46.00K | 19.00K | 28.00K | 39.00K | 33.00K |
| Free cash flow | -53.01M | -54.73M | -65.06M | -76.33M | -86.21M | -78.56M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 54.90M | 28.36M | 6.00M | 601.73M | 621.24M | 0 |
| Ending cash balance | 165.98M | 157.83M | 149.94M | 357.75M | 536.75M | 474.76M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -68.13 | -62.07 | -130.94 | -169.13 | -70.98 | -45.83 |
| ROA %i | -147.38 | -105.18 | -40.08 | -56.07 | -104.95 | -121.41 | -64.03 | -42.68 |
| ROIC %i | -- | -- | -67.54 | -61.49 | -127.88 | -162.45 | -70.45 | -45.77 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -100.25 | -95.79 |
| EBIT margin %i | -- | -- | -- | -- | -- | -5,164.41 | -2,340.29 | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.72 | 6.67 | 19.23 | 7.48 | 3.23 | 5.39 | 10.77 | 10.22 |
| Quick ratioi | 3.49 | 6.57 | 18.87 | 7.18 | 2.93 | 5.16 | 10.45 | 10.03 |
| Debt / assetsi | 0.00 | 3.06 | 0.25 | 1.47 | 3.04 | 2.84 | 0.28 | 0.01 |
| LT debt / equityi | -- | -- | -- | 1.40 | 3.28 | 1.97 | 0.02 | -- |
| Interest coveragei | -206.89 | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -63.56 | -60.98 | -75.20 | -45.83 | -35.32 | -38.86 |
| ROA %i | -58.30 | -56.16 | -67.20 | -42.68 | -33.68 | -36.80 |
| ROIC %i | -63.24 | -60.78 | -74.98 | -45.77 | -35.27 | -38.82 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -2,868.84 | -3,497.57 | -3,927.51 | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.44 | 6.31 | 5.18 | 10.22 | 15.88 | 15.73 |
| Quick ratioi | 8.30 | 6.20 | 5.05 | 10.03 | 15.66 | 15.46 |
| Debt / assetsi | 0.22 | 0.17 | 0.11 | 0.01 | 0.10 | 0.08 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovers and develops therapies for central nervous system (CNS) disorders100.00%
Region
United States100.00%
Quote time 2026-10-08 04:00:01 · For reference only, not investment advice and not tailored to your situation.